Carfilzomib (Kyprolis®) is accepted for restricted use within NHSScotland for treatment of adults with multiple myeloma

Treatment is restricted to pts who have received only one prior therapy. Carfilzomib in combination with lenalidomide and dexamethasone improved progression free survival and overall survival vs lenalidomide and dexamethasone in pts who had received 1-3 prior therapies.

Scottish Medicines Consortium